Camber Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-4,390,000
| Closed | -$41.3M | – | 40 |
|
|
2020
Q3 | $41.3M | Hold |
4,390,000
| – | – | 2.18% | 17 |
|
|
2020
Q2 | $33.6M | Hold |
4,390,000
| – | – | 1.92% | 17 |
|
|
2020
Q1 | $27.1M | Hold |
4,390,000
| – | – | 1.62% | 20 |
|
|
2019
Q4 | $53.4M | Hold |
4,390,000
| – | – | 2.72% | 19 |
|
|
2019
Q3 | $50.7M | Buy |
4,390,000
+1,390,000
| +46% | +$14.6M | 2.67% | 18 |
|
|
2019
Q2 | $30M | Buy |
3,000,000
+350,000
| +13% | +$3.78M | 1.4% | 23 |
|
|
2019
Q1 | $34.1M | Hold |
2,650,000
| – | – | 1.7% | 24 |
|
|
2018
Q4 | $40.3M | Hold |
2,650,000
| – | – | 1.91% | 22 |
|
|
2018
Q3 | $53M | Hold |
2,650,000
| – | – | 2.27% | 17 |
|
|
2018
Q2 | $51.7M | Hold |
2,650,000
| – | – | 1.99% | 25 |
|
|
2018
Q1 | $53.4M | Hold |
2,650,000
| – | – | 2.62% | 17 |
|
|
2017
Q4 | $35.1M | Hold |
2,650,000
| – | – | 1.72% | 20 |
|
|
2017
Q3 | $48.9M | Buy |
2,650,000
+950,000
| +56% | +$17.7M | 3.1% | 15 |
|
|
2017
Q2 | $31.3M | Buy |
+1,700,000
| New | +$33.7M | 1.52% | 20 |
|
|
2017
Q1 | – | Sell |
-611,390
| Closed | -$21.3M | – | 38 |
|
|
2016
Q4 | $21.3M | Hold |
611,390
| – | – | 1.11% | 25 |
|
|
2016
Q3 | $15M | Buy |
611,390
+11,390
| +2% | +$285K | 0.66% | 28 |
|
|
2016
Q2 | $14.4M | Hold |
600,000
| – | – | 0.69% | 35 |
|
|
2016
Q1 | $14M | Buy |
+600,000
| New | +$14.2M | 0.82% | 32 |
|
|
2015
Q2 | – | Sell |
-1,018,246
| Closed | -$55.7M | – | 50 |
|
|
2015
Q1 | $55.7M | Buy |
1,018,246
+18,246
| +2% | +$870K | 3.97% | 9 |
|
|
2014
Q4 | $42.6M | Buy |
1,000,000
+250,000
| +33% | +$9.03M | 2.83% | 12 |
|
|
2014
Q3 | $23.9M | Buy |
+750,000
| New | +$16M | 2.25% | 19 |
|
Camber Capital Management's AMAG Position: Q4 2020 in Review
Camber Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 4,390,000 shares — an estimated $41.3M sold.
Camber Capital Management first reported a position in AMAG in Q3 2014 and held it in 21 quarters. The position peaked at $55.7M in Q1 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Camber Capital Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Camber Capital Management sold 4,390,000 AMAG Pharmaceuticals shares in Q4 2020, an estimated $41.3M.
- Camber Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2014 and held it in 21 quarters.
- Camber Capital Management's AMAG Pharmaceuticals position peaked at $55.7M in Q1 2015.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.